<DOC>
	<DOC>NCT00955357</DOC>
	<brief_summary>To evaluate the efficacy and safety of oral Lacosamide as first add on treatment in subjects with uncontrolled partial-onset seizures after prior treatment with a monotherapy Antiepileptic Drug (AED) regimen compared to subjects who have received treatment with at least 2 AEDs.</brief_summary>
	<brief_title>Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures</brief_title>
	<detailed_description>The study consisted of 3 Periods: Period 1: a 1-week Screening Phase, Period 2: a 30-week Treatment Phase (consisting of a 6-week Titration Phase and a 24-week Maintenance Phase), and Period 3: a 3-week Taper/Safety Follow-Up Phase.</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>Group 1: Subject has a diagnosis of epilepsy with simple partial seizures (motor component) and/or complex partial seizures with or without secondary generalization Currently taking adequate monotherapy (defined as a single Antiepileptic Drug (AED) for at least 28 days prior to Screening) and has no history of AED polytherapy. Prior use of rescue medication (shortterm intermittent use) is acceptable Epilepsy diagnosis should be ≤24 months at the time of the Screening Visit The minimum allowed seizure frequency at any time during the 12 weeks prior to the Screening Visit is ≥3 partialonset seizures Group 2: Subject has a diagnosis of epilepsy with simple partial seizures (motor component) and/or complex partial seizures with or without secondary generalization Currently taking 1 to 3 AEDs, and has tried at least 2 prior AED treatment regimens (concurrently or sequentially) Epilepsy diagnosis should be ≥5 years at the time of the Screening Visit The minimum allowed seizure frequency during the 12 weeks prior to the Screening Visit is ≥1 partialonset seizure per 28 days Previous use of Lacosamide History of seizure disorder characterized primarily by isolated auras History of primary generalized seizures History of status epilepticus within last 12months History of cluster seizures during the 12 week period prior to Visit 1 Nonepileptic events, including pseudoseizures that could be confused with seizure Lifetime history of suicide attempt or suicidal ideation in the past 6 months Hypersensitivity to any component of Lacosamide History of drug or alcohol abuse History of an acute or subacutely progressive Central Nervous System (CNS) disease Undergone cranial surgery within the last year prior to study entry Concomitant treatment of Felbamate or previous Felbamate therapy within the last 6 months Prior or concomitant Vigabatrin use</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Epilepsy Treatment</keyword>
	<keyword>Anti-epileptic drugs</keyword>
	<keyword>Seizures</keyword>
	<keyword>Vimpat</keyword>
</DOC>